Nasdaq:US$16.36 (+0.53) | HKEX:HK$25.75 (+0.70) | AIM:£2.67 (+0.07)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 3 Jun 2014

ASCO 2014: A phase 1b study of VEGFR inhibitor fruquintinib in patients with pretreated advanced colorectal cancer